14/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Scientific Data Research Center

NIH APOL 1长期移植结果网络（APOLLO）协作U 01正在执行一项 美国肾脏供体和受体载脂蛋白L1基因（APOL 1）风险变异的国家前瞻性评估 非裔美国人捐赠者的移植，以确定其对移植结果的影响。此外，后 将评估非裔美国人活体肾脏捐赠者的捐赠健康和肾功能。我们正在申请 阿波罗科学与数据研究中心（SDRC）肾移植存活期缩短 观察到来自已故非洲裔美国人肾脏捐赠者的移植，相对于已故欧洲人， 美国肾脏捐赠者其原因尚不清楚，但回顾性报告表明，存在两个 肾脏供体中的APOL 1风险变异可能导致这种差异。这些变异在人群中很常见 最近的非洲血统（如非洲裔美国人），他们与慢性肾脏病密切相关 疾病，但在其他种族/族裔群体中罕见。APOL 1基因型数据可以提供更准确的评估 的可能性，长期肾移植功能的供体肾，从而提高匹配的供体 为了优化肾移植和患者存活率，该信息可以 在做出分配决定之前，更好地告知医生器官质量。它还可以告知安全 活体肾脏捐赠在APOL 1基因型可用于临床之前， 需要进行一项研究，以评估非裔美国人捐赠者和接受者的肾移植结果。 基于APOL 1的肾脏。APOLLO收集了回顾性研究中缺乏的信息，包括接受者 APOL 1基因型、移植肾中的肾组织学和BK病毒感染的存在或发展， 供体特异性抗体和肾移植后急性排斥反应。我们申请继续执行 APOLLO网络的这些活动：总体研究协调，协助确保遵守 方案和程序手册，维护数据跟踪工具和研究网站，收集和存档 临床和结局数据，进行基因分型，统计分析，结局评估，包括 主要结局“基于供体的非裔美国人供体移植肾的移植失败时间 APOL 1基因型”，并完成生物储存库。我们将纵向评估生命状态，肾功能 基于APOL 1基因型的非裔美国人活体供肾者的尿蛋白和尿蛋白， 供体APOL 1基因型对血清肌酐浓度、估计肾小球滤过率和 功能正常的肾移植受者的蛋白尿APOLLO的结果有可能改变 肾移植中的器官分配和知情同意过程，优化肾移植物存活率， 减少优质肾脏的丢弃，保护活体供肾者的健康。

The NIH APOL1 Long-term Transplantation Outcomes Network (APOLLO) Collaborative U01 is performing a national prospective evaluation of donor and recipient apolipoprotein L1 gene (APOL1) risk variants in US kidney transplants from African American donors to determine their effect on transplant outcomes. In addition, post- donation health and kidney function of African American living kidney donors will be assessed. We are applying to continue serving as the APOLLO Scientific and Data Research Center (SDRC). Shorter renal allograft survival is observed for transplantations from deceased African American kidney donors, relative to deceased European American kidney donors. Reasons for this are unknown, but retrospective reports suggest that presence of two APOL1 risk variants in kidney donors may contribute to the disparity. These variants are common in populations with recent African ancestry (such as African Americans), where they are strongly associated with chronic kidney disease, but rare in other racial/ethnic groups. APOL1 genotype data may provide more accurate assessment of the likelihood for long-term renal allograft function in donor kidneys, thereby improving matching of donor kidneys with potential recipients in order to optimize renal allograft and patient survival. This information may better inform physicians about organ quality prior to making decisions on allocation. It may also inform the safety of living kidney donation. Before APOL1 genotypes can be used clinically, the prospective national APOLLO study was required to evaluate kidney transplant outcomes from African American donors and recipients of their kidneys based on APOL1. APOLLO collects information lacking from retrospective studies, including recipient APOL1 genotypes, renal histology in engrafted kidneys and presence or development of BK viral infections, donor specific antibodies, and acute rejections after kidney transplantation. We apply to continue to perform these activities for the APOLLO Network: overall study coordination, assist with ensuring compliance with the Protocol and Manual of Procedures, maintain data tracking tools and the study website, collect and archive clinical and outcomes data, perform genotyping, statistical analyses, assessment of outcomes including the primary outcome “time to allograft failure in transplanted kidneys from African American donors based on donor APOL1 genotypes”, and complete the bio-repository. We will longitudinally assess vital status, kidney function and proteinuria in living African American kidney donors based on APOL1 genotypes and prospectively assess effects of donor APOL1 genotypes on serum creatinine concentration, estimated glomerular filtration rate, and proteinuria in kidney transplant recipients with functioning grafts. APOLLO results have the potential to transform the organ allocation and informed consent processes in kidney transplantation, optimize renal allograft survival, reduce discard of good-quality kidneys, and protect the health of living kidney donors.